Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549)

BMC Pharmacology

Volumn 7, Issue , 2007, Pages

  Nonaka, Takashi ^a   Nave, Rüdiger ^b   McCracken, Nigel ^b   Kawashimo, Atsuko ^a   Katsuura, Yasuhiro ^a  

^a TEIJIN PHARMA LIMITED   (Japan)

^b Nycomed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; DRUG METABOLITE; FATTY ACID ESTER; FLUTICASONE PROPIONATE; OLEIC ACID; PALMITIC ACID; PREGNANE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG RELEASE; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; TANDEM MASS SPECTROMETRY; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; EPITHELIUM CELL; LUNG ALVEOLUS; METABOLISM; RESPIRATORY TRACT MUCOSA;

CELL LINE; EPITHELIAL CELLS; HUMANS; PREGNENEDIONES; PULMONARY ALVEOLI; RESPIRATORY MUCOSA;

EID: 35748979427     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-7-12     Document Type: Article

References (30)

1. Georgitis JW The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute Chest 1999, 115:210-217. 9925086
2. Williams SG Schmidt DK Redd SC Storms W Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program MMWR Recomm Rep 2003, 52:1-8. 12696781
3. Barnes PJ Pedersen S Busse WW Efficacy and safety of inhaled corticosteroids. New developments Am J Respir Crit Care Med 1998, 157:S1-53. 9520807
4. Derendorf H Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety Respir Med 1997, 91Suppl A:22-28. 9474364
5. Rohatagi S Appajosyula S Derendorf H Szefler S Nave R Zech K Banerji D Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/ pharmacodynamic perspective J Clin Pharmacol 2004, 44:37-47. 14681340
6. Hochhaus G Mollmann H Derendorf H Gonzalez-Rothi RJ Pharmacokinetic/ pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model J Clin Pharmacol 1997, 37:881-892. 9505979
7. Dietzel K Engelstatter R Keller A Ciclesonide: An on-site-activated steroid New drugs for asthma, allergy and COPD Basel, Karger Hansel TT and Barnes PJ Prog Respir Res; 2001: 91-93.
8. Mealy NE Bayes M Castaner J Ciclesonide Drugs of the future 2001, 26:1033-1039.
9. Nave R Wingertzahn MA Brookman S Kaida S Matsunaga T Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis J Clin Pharmacol 2006, 46:461-467. 16554455
10. Dent G Ciclesonide (Byk Gulden) Current Opinion in Investigational Drugs 2002, 3:78-83. 12054077
11. Derendorf H Nave R Drollmann A Cerasoli F Wurst W Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Eur Respir J 2006, 28:1042-1050. 17074919
12. Pedersen S O'Byrne P A comparison of the efficacy and safety of inhaled corticosteroids in asthma Allergy 1997, 52:1-34. 9253465
13. Lipworth BJ Jackson CM Safety of inhaled and intranasal corticosteroids: lessons for the new millennium Drug Saf 2000, 23:11-33. 10915030
14. Edsbacker S Brattsand R Budesonide fatty-acid esterification: A novel mechanism prolonging binding to airway tissue. Review of available data Ann Allergy Asthma Immunol 2002, 88:609-616. 12086369
15. Tunek A Sjodin K Hallstrom G Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes Drug Metab Dispos 1997, 25:1311-1317. 9351909
16. Nave R Hummel RP Wohlsen A Herzog R Zech K The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices American Journal of Respiratory and Critical Care Medicine ATS 2004; 2004,169: A91.
17. Nave R Meyer W Fuhst R Zech K Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide Pulm Pharmacol Ther 2005, 18:390-396. 16179214
18. Nave R Fisher R Zech K In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices Biopharm Drug Dispos 2006, 27:197-207. 16566061
19. Foster KA Oster CG Mayer MM Avery ML Audus KL Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism Exp Cell Res 1998, 243:359-366. 9743595
20. Kelly HW Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids Ann Allergy Asthma Immunol 2003, 91:326-334. 14582810
21. Barnes PJ Pathophysiology of asthma Br J Clin Pharmacol 1996, 42:3-10. 8807137
22. Schweibert LM Stellato C Schleimer RP The epithelium as a target of glucocorticoid action in the treatment of asthma Am J Respir Crit Care Med 1996, 154:S16-S19. 8756782
23. Drollmann A Watz H Nave R Boss H Magnussen H Hoffmann H In vivo metabolism of ciclesonide in the human lung Proc Am Thorac Soc ATS 2006, San Diego, USA 2006, 3:A75.
24. Nonaka T Sugiyama H Kishimoto T Horiuchi H Taneda M Sakuma Y Hoshina K Kamimura T Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro European Respiratory Journal 2002, 20:P652.
25. Postma DS Sevette C Martinat Y Schloesser N Aumann J Kafé H Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening Eur Respir J 2001, 17:1083-1088. 11491148
26. Chapman KR Patel P D'Urzo AD Alexander M Mehra S Oedekoven C Engelstatter R Boulet LP Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma Allergy 2005, 60:330-337. 15679718
27. Langdon CG Adler M Mehra S Alexander M Drollmann A Once-daily ciclesonide 80 or 320mug for 12 weeks is safe and effective in patients with persistent asthma Respir Med 2005, 99:1275-1285. 16024244
28. Niphadkar P Jagannath K Joshi JM Awad N Boss H Hellbardt S Gadgil DA Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study Clin Ther 2005, 27:1752-1763. 16368446
29. Boulet LP Drollmann A Magyar P Timar M Knight A Engelstatter R Fabbri L Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma Respir Med 2006, 100:785-794. 16427266
30. Buhl R Vinkler I Magyar P Gyori Z Rybacki C Middle MV Escher A Engelstatter R Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma Pulm Pharmacol Ther 2006, 19:404-412. 16310388